Finance

Beta
Lists
PCVX:NASDAQ
Vaxcyte Inc
$53.86
-0.01%
(-0.0050) 1D
Jun 25, 1:59:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PCVX...
Open
$53.36
High
$55.88
Low
$53.12
Mkt. cap
7.81B
Avg. vol.
1.51M
Volume
545.17K
52-wk high
$64.78
52-wk low
$29.10
EPS
-$6.89
Beta
1.24
Shares outstanding
144.40M
No. of employees
507
Open
$53.36
High
$55.88
Low
$53.12
Mkt. cap
7.81B
Avg. vol.
1.51M
Volume
545.17K
52-wk high
$64.78
52-wk low
$29.10
EPS
-$6.89
Beta
1.24
Shares outstanding
144.40M
No. of employees
507
News stories
From sources across the web
About Vaxcyte Inc
CEO-
Employees507
Founded2013
HeadquartersSan Carlos, California, United States
SectorBiotechnology
Websitevaxcyte.com
Analyst ratings
Based on 6 analysts giving stock ratings to PCVX in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for PCVX in the last 3 months.
Highest
Current $53.86
$163.00 (+202.61%)
Average
$116.00 (+115.35%)
Lowest
$75.00 (+39.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Salim Syed
Mizuho Securities
Buy
Maintained
$163.00
+202.6%
06/18/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$116.00
+115.4%
06/03/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
05/21/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
05/07/2026
Joseph Stringer
Needham
Buy
Reiterated
$110.00
+104.2%
05/07/2026
Tara Bancroft
TD Cowen
Buy
Maintained
$75.00
+39.2%
05/06/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$163.00
+202.6%
03/24/2026
Thomas Shrader
BTIG
Buy
Maintained
$89.00
+65.2%
03/02/2026
Unknown Analyst
Jefferies
Buy
Maintained
$146.00
+171%
02/25/2026
Asad Haider
Goldman Sachs
Hold
Maintained
$67.00
+24.4%
02/26/2026
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$2.30 / -$1.77
-29.65%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
194.18M
209.93M
242.06M
312.78M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
32.04M
32.45M
32.22M
33.07M
Operating expense
226.22M
242.38M
274.28M
345.85M
Total operating expenses
226.22M
242.38M
274.28M
345.85M
Operating income
-226.22M
-242.38M
-274.28M
-345.85M
Other non operating income
28.57M
291.00K
1.32M
-1.38M
EBT including unusual items
-166.57M
-212.83M
-246.51M
-320.62M
EBT excluding unusual items
-166.57M
-212.83M
-246.51M
-320.62M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-166.57M
-212.83M
-246.51M
-320.62M
Net profit margin
-
-
-
-
Earnings per share
-1.22
-1.56
-1.80
-2.30
Interest and investment income
31.07M
29.26M
26.45M
26.61M
Interest expense
-
-
-
-
Net interest expenses
31.07M
29.26M
26.45M
26.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
-223.34M
-239.32M
-266.79M
-342.90M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of PCVX
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer